Vaccines leadership Global leadership in smallpox and mpox vaccines with a long-standing U.S. government partnership presents a strong credibility anchor for engaging public health buyers and international distributors seeking proven, regulatory-ready vaccine platforms.

Manufacturing expansion Recent investment in a commercial manufacturing facility signals capacity growth and readiness to meet rising demand, offering sales opportunities in contract manufacturing, technology transfer, and scalable production partnerships.

Distribution partnerships Strategic distribution deals, including Eurofarma exclusivity for chikungunya in Brazil and Nordea-led share program activity, indicate openness to licensed commercialization and regional market expansion—target markets with traveler and endemic disease vaccines.

Leadership changes Board appointments from industry leaders and investor relations leadership changes point to evolving governance and strategic focus, creating opening to engage on strategic partnerships, funding rounds, and performance milestones.

Financial health signals Mid-market revenue range with substantial funding and active capital market activity (buy-backs, private equity interest) suggests opportunities for collaboration on late-stage development, commercialization financing, and strategic investments.